• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

活化的人表皮生长因子受体的酪氨酸1148和1173是完整细胞中Shc的结合位点。

Tyrosines 1148 and 1173 of activated human epidermal growth factor receptors are binding sites of Shc in intact cells.

作者信息

Okabayashi Y, Kido Y, Okutani T, Sugimoto Y, Sakaguchi K, Kasuga M

机构信息

Second Department of Internal Medicine, Kobe University School of Medicine, Japan.

出版信息

J Biol Chem. 1994 Jul 15;269(28):18674-8.

PMID:8034616
Abstract

Autophosphorylation of receptor tyrosine kinases provides binding sites for signaling proteins containing Src homology 2 (SH2) domains. We determined the binding sites of Shc, SH2-containing adaptor protein, within epidermal growth factor (EGF) receptors, using Chinese hamster ovary cells overexpressing EGF receptor mutants in which autophosphorylation sites, either alone or in combination, were replaced by phenylalanine. Binding of Shc to EGF receptor mutants lacking single tyrosine residues at 1148 or 1173 decreased by approximately 60 or approximately 15%, respectively, whereas other single point mutants bound the wild-type level of Shc. Binding of Shc markedly decreased in mutants lacking both tyrosine residues at 1148 and 1173. In peptide inhibition assay, phosphorylated nonameric peptide representing tyrosine 1148, DNPDpYQQDF, but not pentameric peptide, pYQQDF, inhibited the binding of glutathione S-transferase-Shc SH2 domain fusion protein to in vitro autophosphorylated EGF receptors, suggesting that N-terminal sequences adjacent to phosphotyrosine are necessary for the association of Shc. Based on results of peptide inhibition assays in which phosphorylated peptides representing tyrosines 992, 1148, and 1173 inhibited Shc binding to the receptor, we constructed another EGF receptor mutant in which one of these tyrosine residues was retained. The amount of Shc bound to mutant receptors retaining tyrosines 1148, 1173, or 992 was approximately 80, approximately 40, or approximately 10% of wild-type level, respectively. These results indicate that tyrosine 1148 of activated human EGF receptors is a major binding site of Shc and tyrosine 1173 is a secondary binding site in intact cells.

摘要

受体酪氨酸激酶的自磷酸化作用为含有Src同源结构域2(SH2结构域)的信号蛋白提供了结合位点。我们利用过表达表皮生长因子(EGF)受体突变体的中国仓鼠卵巢细胞,确定了含SH2结构域的衔接蛋白Shc在EGF受体中的结合位点,这些突变体的自磷酸化位点单独或组合被苯丙氨酸取代。Shc与在1148或1173位缺乏单个酪氨酸残基的EGF受体突变体的结合分别减少了约60%或约15%,而其他单点突变体与Shc的结合水平与野生型相当。在1148和1173位均缺乏酪氨酸残基的突变体中,Shc的结合显著减少。在肽抑制试验中,代表酪氨酸1148的磷酸化九聚体肽DNPDpYQQDF可抑制谷胱甘肽S-转移酶-Shc SH2结构域融合蛋白与体外自磷酸化的EGF受体的结合,而五聚体肽pYQQDF则无此作用,这表明磷酸酪氨酸附近的N端序列对于Shc的结合是必需的。基于代表酪氨酸992、1148和1173的磷酸化肽抑制Shc与受体结合的肽抑制试验结果,我们构建了另一种EGF受体突变体,其中保留了这些酪氨酸残基之一。与保留酪氨酸1148、1173或992的突变体受体结合的Shc量分别约为野生型水平的80%、40%或10%。这些结果表明,活化的人EGF受体的酪氨酸1148是Shc的主要结合位点,酪氨酸1173是完整细胞中的次要结合位点。

相似文献

1
Tyrosines 1148 and 1173 of activated human epidermal growth factor receptors are binding sites of Shc in intact cells.活化的人表皮生长因子受体的酪氨酸1148和1173是完整细胞中Shc的结合位点。
J Biol Chem. 1994 Jul 15;269(28):18674-8.
2
A conserved amino-terminal Shc domain binds to phosphotyrosine motifs in activated receptors and phosphopeptides.一个保守的氨基末端Shc结构域与活化受体和磷酸肽中的磷酸酪氨酸基序结合。
Curr Biol. 1995 Apr 1;5(4):404-12. doi: 10.1016/s0960-9822(95)00081-9.
3
Shc phosphotyrosine-binding domain dominantly interacts with epidermal growth factor receptors and mediates Ras activation in intact cells.Shc磷酸酪氨酸结合结构域主要与表皮生长因子受体相互作用,并在完整细胞中介导Ras激活。
Mol Endocrinol. 1998 Apr;12(4):536-43. doi: 10.1210/mend.12.4.0094.
4
Grb2/Ash binds directly to tyrosines 1068 and 1086 and indirectly to tyrosine 1148 of activated human epidermal growth factor receptors in intact cells.
J Biol Chem. 1994 Dec 9;269(49):31310-4.
5
Epidermal growth factor receptors containing a single tyrosine in their C-terminal tail bind different effector molecules and are signaling-competent.在其C末端尾巴中含有单个酪氨酸的表皮生长因子受体可结合不同的效应分子并具有信号传导能力。
J Biol Chem. 2017 Dec 15;292(50):20744-20755. doi: 10.1074/jbc.M117.802553. Epub 2017 Oct 26.
6
Functional importance of amino-terminal domain of Shc for interaction with insulin and epidermal growth factor receptors in phosphorylation-independent manner.Shc氨基末端结构域以不依赖磷酸化的方式与胰岛素和表皮生长因子受体相互作用的功能重要性。
J Biol Chem. 1996 Aug 16;271(33):20082-7. doi: 10.1074/jbc.271.33.20082.
7
Ligand regulates epidermal growth factor receptor kinase specificity: activation increases preference for GAB1 and SHC versus autophosphorylation sites.配体调节表皮生长因子受体激酶特异性:激活增加对GAB1和SHC而非自身磷酸化位点的偏好。
J Biol Chem. 2004 Sep 10;279(37):38143-50. doi: 10.1074/jbc.M405760200. Epub 2004 Jul 1.
8
SH2 domains prevent tyrosine dephosphorylation of the EGF receptor: identification of Tyr992 as the high-affinity binding site for SH2 domains of phospholipase C gamma.SH2结构域可防止表皮生长因子受体的酪氨酸去磷酸化:确定酪氨酸992为磷脂酶Cγ的SH2结构域的高亲和力结合位点。
EMBO J. 1992 Feb;11(2):559-67. doi: 10.1002/j.1460-2075.1992.tb05087.x.
9
Structural requirements of the epidermal growth factor receptor for tyrosine phosphorylation of eps8 and eps15, substrates lacking Src SH2 homology domains.表皮生长因子受体对eps8和eps15进行酪氨酸磷酸化的结构要求,eps8和eps15是缺乏Src SH2同源结构域的底物。
J Biol Chem. 1995 Jul 7;270(27):16271-6. doi: 10.1074/jbc.270.27.16271.
10
Epidermal growth factor-receptor mutant lacking the autophosphorylation sites induces phosphorylation of Shc protein and Shc-Grb2/ASH association and retains mitogenic activity.缺乏自身磷酸化位点的表皮生长因子受体突变体可诱导Shc蛋白磷酸化及Shc与Grb2/ASH结合,并保留促有丝分裂活性。
Proc Natl Acad Sci U S A. 1994 Jan 4;91(1):167-71. doi: 10.1073/pnas.91.1.167.

引用本文的文献

1
Ethyl acetate extract of : a specific and potent inhibitor against the drug-resistant EGFR_T790M mutant in NSCLC.……的乙酸乙酯提取物:一种针对非小细胞肺癌中耐药性EGFR_T790M突变体的特异性强效抑制剂。 需注意,原文中“Ethyl acetate extract of :”这里冒号前缺少具体所指内容,翻译时只能按省略号表示。
Front Pharmacol. 2025 Apr 29;16:1570108. doi: 10.3389/fphar.2025.1570108. eCollection 2025.
2
Targeting the PI3K/AKT/mTOR pathway in lung cancer: mechanisms and therapeutic targeting.靶向肺癌中的PI3K/AKT/mTOR信号通路:作用机制与治疗靶点
Front Pharmacol. 2025 Feb 18;16:1516583. doi: 10.3389/fphar.2025.1516583. eCollection 2025.
3
The impact of nitric oxide on HER family post-translational modification and downstream signaling in cancer.
一氧化氮对癌症中HER家族翻译后修饰及下游信号传导的影响。
Front Physiol. 2024 Mar 27;15:1358850. doi: 10.3389/fphys.2024.1358850. eCollection 2024.
4
Roles of epidermal growth factor receptor, claudin-1 and occludin in multi-step entry of hepatitis C virus into polarized hepatoma spheroids.表皮生长因子受体、紧密连接蛋白-1 和闭合蛋白在丙型肝炎病毒进入极化肝癌球体的多步进入中的作用。
PLoS Pathog. 2023 Dec 29;19(12):e1011887. doi: 10.1371/journal.ppat.1011887. eCollection 2023 Dec.
5
Predictive data-driven modeling of C-terminal tyrosine function in the EGFR signaling network.EGFR 信号网络中 C 末端酪氨酸功能的预测性数据驱动建模。
Life Sci Alliance. 2023 May 11;6(8). doi: 10.26508/lsa.202201466. Print 2023 Aug.
6
Hepatocyte Growth Factor Enhances Antineoplastic Effect of 5-Fluorouracil by Increasing UPP1 Expression in HepG2 Cells.肝细胞生长因子通过增加 HepG2 细胞中 UPP1 的表达增强 5-氟尿嘧啶的抗肿瘤作用。
Int J Mol Sci. 2022 Aug 14;23(16):9108. doi: 10.3390/ijms23169108.
7
MERTK activation drives osimertinib resistance in EGFR-mutant non-small cell lung cancer.MERTK 激活导致 EGFR 突变型非小细胞肺癌对奥希替尼产生耐药性。
J Clin Invest. 2022 Aug 1;132(15). doi: 10.1172/JCI150517.
8
Interactions between EGFR and EphA2 promote tumorigenesis through the action of Ephexin1.EGFR 与 EphA2 之间的相互作用通过 Ephexin1 的作用促进肿瘤发生。
Cell Death Dis. 2022 Jun 6;13(6):528. doi: 10.1038/s41419-022-04984-6.
9
Precision medicine for metastatic colorectal cancer in clinical practice.临床实践中转移性结直肠癌的精准医学
Ther Adv Med Oncol. 2022 Jan 19;14:17588359211072703. doi: 10.1177/17588359211072703. eCollection 2022.
10
Soluble SORLA Enhances Neurite Outgrowth and Regeneration through Activation of the EGF Receptor/ERK Signaling Axis.可溶性 SORLA 通过激活 EGF 受体/ERK 信号通路增强神经突生长和再生。
J Neurosci. 2020 Jul 29;40(31):5908-5921. doi: 10.1523/JNEUROSCI.0723-20.2020. Epub 2020 Jun 29.